Ríos, José http://orcid.org/0000-0002-0716-8784
Sapena, Víctor http://orcid.org/0000-0003-4379-6486
Mariño, Zoe http://orcid.org/0000-0001-6321-9534
Bruix, Jordi http://orcid.org/0000-0002-9826-0753
Forns, Xavier http://orcid.org/0000-0002-8188-1764
Morros, Rosa http://orcid.org/0000-0001-6752-8748
Reig, María http://orcid.org/0000-0002-5711-9534
Torres, Ferran http://orcid.org/0000-0002-7355-7913
Pontes, Caridad http://orcid.org/0000-0002-3274-6048
Funding for this research was provided by:
Ministerio de Sanidad, Consumo y Bienestar Social
Instituto de Salud Carlos III (18/00768, PI18/0358, PI15/00145)
Asociación española contra el cáncer (PI044031)
Generalitat de Catalunya (16-0026)
Article History
Accepted: 28 May 2024
First Online: 14 June 2024
Declarations
:
: Grant support was received from the Spanish National Health Ministry (National Strategic Plan Against Hepatitis), Instituto de Salud Carlos III (PI18/00768, PI15/00145, PI18/0358), Spanish Association Against Cancer (AECC) [PI044031], CERCA Programme/Generalitat de Catalunya, and World Wide Cancer Research (Association for International Cancer Research) 16-0026.
: José Ríos has received educational/training fees from Amgen, AstraZeneca, Boehringer Ingelheim, Janssen-Cilag, Novartis, and Lilly. Zoe Mariño has received consultancy fees from Gilead, AbbVie, Alexion, Orphalan, and Deep Genomics, speaker fees from Gilead and AbbVie, and research grants from Gilead. Víctor Sapena has received travel grants from Bayer and consultancy fees from Leo Pharma. Jordi Bruix has been a consultant for Arqule, Bayer-Shering Pharma, Novartis, BMS, BTG-Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano, and Sanofi, has received research/educational grants from Bayer, and lecture fees from Bayer-Shering Pharma, BTG-Biocompatibles, Eisai, Terumo, Sirtex, and Ipsen. Xavier Forns acted as an advisor for Gilead and received a grant from AbbVie. María Reig has received consultancy fees from Bayer, BMS, Roche, Ipsen, AstraZeneca, and Lilly, lecture fees from Bayer, BMS, Gilead, and Lilly, and research grants from Bayer and Ipsen. Ferran Torres has received fees for the Data and Safety Monitoring Board from Basilea Pharmaceutica International and ROVI, and educational/training fees from Janssen and Ferrer. Rosa Morros and Caridad Pontes have no conflicts of interest that are directly relevant to the content of this article.
: The study protocol was approved by the Ethics Committee for Clinical Research of the Institute of Research in Primary Care (IDIAP Jordi Gol, code CEI P17/061).
: Patients’ informed consent was waived because of the retrospective design and the pseudo-anonymization of the data collected from electronic databases.
: Not applicable.
: Study data are available from the author (JR) upon request.
: Not applicable.
: JR, JB, RM, MR, FT, and CP: concept and design of the study. ZM, VS, XF, RM, MR, and CP: data collection. JR, VS, and FT: statistical analysis. JR, JB, CP, and FT: interpretation of results. JR: drafting of the initial manuscript. ZM, VS, JB, XF, RM, MR, FT, and CP: draft review for important intellectual content. All authors read and approved the final version.